SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andreas Helke who wrote (15850)2/25/1998 12:12:00 PM
From: Henry Niman  Respond to of 32384
 
Andreas, The European Type II diabetes trial is designed to determine an effective dose. Most of the cancer trials use the maximum tolerated dose, which is higher. Targretin should be on pharmacy shelves next year for cancer. Diabetes is projected for 2002, I believe. I suspect that most of the initial off-label use will be for cancer (clinical data for diabetes trails cancer and risk/reward ration is better for cancer).



To: Andreas Helke who wrote (15850)2/25/1998 12:21:00 PM
From: Webhead  Read Replies (4) | Respond to of 32384
 
I'm kind of surprised about the (thusfar) "ho hum" reaction to Ligand's licensing via Glyomed. After all, $900,000 will buy a lot of disposable pipette tips for Ligand's screening program and obligates ligand to nothing other that accepting future milestone and royalties should Cytel move anything through phaseIII. Isn't this just pure cream!?

Ed


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News